Cosmos Holdings Files For Mixed Shelf Offering Of Up To $50M

– Reuters Citing SEC Filing

byBenzinga Newsdesk

September 22, 2022

1 minute read

– Reuters Citing SEC Filing

Truist Securities Initiates Coverage On Target with Buy Rating, Announces Price Target of $270

By Benzinga Newsdesk

Today, 10:48 PM

Truist Securities analyst Scot Ciccarelli initiates coverage on Target (NYSE:TGT) with a Buy rating and announces Price Target of $270.

TGT

New Pacific Metals Q2 EPS $(0.03) Down From $(0.01) YoY

By Michael Horton

Today, 10:48 PM

New Pacific Metals (AMEX:NEWP) reported quarterly losses of $(0.03) per share. This is a 200 percent decrease over losses of $(0.01) per share from the same period last year.

NEWP

Medical Cannabis For Autism: Zelira Receives $8.6M For FDA Clinical Trials For Treatment

By Joana Scopel

Today, 10:48 PM

Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a developer of cannabinoid-based medicines, will conduct FDA Phase 2 and Phase 3 clinical trials for its HOPE-1 treatment of Autism Spectrum Disorder (ASD).

ZLDAF

TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development

By Vandana Singh

Today, 10:48 PM

TransCode Therapeutics Inc (NASDAQ: RNAZ) has received a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support developing TTX-MC138. TTX-MC138 is TransCode's lead therapeutic candidate for the treatment of metastatic solid tumors.

RNAZ

Cosmos Holdings Files For Mixed Shelf Offering Of Up To $50M

Related Posts

Truist Securities Initiates Coverage On Target with Buy Rating, Announces Price Target of $270

New Pacific Metals Q2 EPS $(0.03) Down From $(0.01) YoY

Medical Cannabis For Autism: Zelira Receives $8.6M For FDA Clinical Trials For Treatment

TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development